loss of dopamine ( 30-40 % ) in the hypothalamus of affected patients has been shown in recent studies , and is compatible with the reported abnormalities of growth hormone release in response to l-dopa administration , elevated plasma levels of msh , and reduced csf levels of somatostatin and beta-endorphins in these patients .
C0020663
hypothalamus
C0037659
somatostatin